Vossler David G, Conry Joan A, Murphy Jerome V
Epilepsy Center, Washington Neuroscience Institute, Renton, Washington 98055, USA.
Epileptic Disord. 2008 Mar;10(1):31-4. doi: 10.1684/epd.2008.0168.
To examine the safety and efficacy of zonisamide in treating myoclonic seizures associated with progressive myoclonic epilepsy (PME), in an open-label setting.
Thirty patients with refractory PME (aged > or = 5 years), who were taking up to three antiepileptic drugs, received adjunctive zonisamide (< or = 6 mg/kg/day) therapy for 16 weeks. Myoclonic seizures were recorded daily over a 24-hour period or in 10-minute epochs in the morning, afternoon, and evening. Safety was assessed via adverse events (AEs); efficacy was measured by the percentage of patients experiencing a > or = 50% decrease in myoclonic seizure frequency from baseline.
Treatment-related AEs, experienced by 53% (n = 16/30) of patients, led to five patients discontinuing zonisamide. The most common AEs were decreased appetite, somnolence, and asthenia. Overall, 36% of patients (n = 10/28) had a > or = 50% reduction in myoclonic seizure frequency.
These results suggest that zonisamide may be useful in the treatment of patients with PME. However, due to the size and open-label character of this study, further research is required.
在开放标签的情况下，研究唑尼沙胺治疗与进行性肌阵挛癫痫（PME）相关的肌阵挛发作的安全性和有效性。
30例难治性PME患者（年龄≥5岁），正在服用多达三种抗癫痫药物，接受辅助唑尼沙胺（≤6mg/kg/天）治疗16周。在24小时内每天记录肌阵挛发作情况，或在上午、下午和晚上以10分钟为时段进行记录。通过不良事件（AE）评估安全性；通过肌阵挛发作频率较基线降低≥50%的患者百分比来衡量疗效。
53%（n=16/30）的患者出现与治疗相关的不良事件，导致5例患者停用唑尼沙胺。最常见的不良事件是食欲减退、嗜睡和乏力。总体而言，36%的患者（n=10/28）肌阵挛发作频率降低≥50%。
这些结果表明唑尼沙胺可能对PME患者的治疗有用。然而，由于本研究的规模和开放标签性质，需要进一步研究。
